La Tuberculosis a 110 años del premio Nobel de Koch
- Autores
- Ritacco, Viviana; de Kantor, Isabel N.
- Año de publicación
- 2015
- Idioma
- español castellano
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: Ritacco, Viviana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: de Kantor, Isabel N. Consultora en Tuberculosis, Buenos Aires; Argentina.
The Nobel Prize in Physiology or Medicine was awarded in 1905 to Robert Koch "for his investigations and discoveries in relation to tuberculosis (TB)". He discovered the causal agent of TB, described the four principles that since then have guided research in communicable diseases and also prepared the old tuberculin, a bacillary extract that failed as a healing element but allowed the early diagnosis of TB infection and promoted the understanding of cellular immunity. After his death, the most conspicuous achievements against TB were the BCG vaccine, and the discovery of streptomycin, the antibiotic that launched the era of the effective treatment of TB. Drug-resistance soon appeared. In Argentina, studies on drug resistance began in the 60s. In the 70s, shortened anti-TB drug schemes were introduced consisting in two-month treatment with four drugs, followed by four months with two drugs. The incidence of TB decreased worldwide, but the immune depression associated with awarded together with the misuse of anti-TB drugs allowed the emergence of multidrug resistance and extensive resistance, with the emergence of nosocomial outbreaks worldwide, including Argentina. New rapid diagnostic methods based on molecular biology were developed and also new drugs, but the treatment of multidrug resistant and extensively resistant TB is still difficult and expensive. TB research has marked several milestones in medical sciences, including the monumental Koch postulates, the tuberculin skin test that laid the basis for understanding cell-mediated immunity, the first design of randomized clinical trials and the use of combined multi-drug treatments. - Fuente
- Medicina (Buenos Aires) 2015;75(6):396-403.
- Materia
-
Tuberculosis
Antituberculosos - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- Repositorio
- Institución
- Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
- OAI Identificador
- oai:sgc.anlis.gob.ar:Publications/123456789/2115
Ver los metadatos del registro completo
id |
SGCANLIS_ad43413e9506444bf34ad3a7af036f57 |
---|---|
oai_identifier_str |
oai:sgc.anlis.gob.ar:Publications/123456789/2115 |
network_acronym_str |
SGCANLIS |
repository_id_str |
a |
network_name_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
spelling |
La Tuberculosis a 110 años del premio Nobel de KochTuberculosis 110 years after the Nobel Prize awarded to KochRitacco, Vivianade Kantor, Isabel N.TuberculosisAntituberculososFil: Ritacco, Viviana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: de Kantor, Isabel N. Consultora en Tuberculosis, Buenos Aires; Argentina.The Nobel Prize in Physiology or Medicine was awarded in 1905 to Robert Koch "for his investigations and discoveries in relation to tuberculosis (TB)". He discovered the causal agent of TB, described the four principles that since then have guided research in communicable diseases and also prepared the old tuberculin, a bacillary extract that failed as a healing element but allowed the early diagnosis of TB infection and promoted the understanding of cellular immunity. After his death, the most conspicuous achievements against TB were the BCG vaccine, and the discovery of streptomycin, the antibiotic that launched the era of the effective treatment of TB. Drug-resistance soon appeared. In Argentina, studies on drug resistance began in the 60s. In the 70s, shortened anti-TB drug schemes were introduced consisting in two-month treatment with four drugs, followed by four months with two drugs. The incidence of TB decreased worldwide, but the immune depression associated with awarded together with the misuse of anti-TB drugs allowed the emergence of multidrug resistance and extensive resistance, with the emergence of nosocomial outbreaks worldwide, including Argentina. New rapid diagnostic methods based on molecular biology were developed and also new drugs, but the treatment of multidrug resistant and extensively resistant TB is still difficult and expensive. TB research has marked several milestones in medical sciences, including the monumental Koch postulates, the tuberculin skin test that laid the basis for understanding cell-mediated immunity, the first design of randomized clinical trials and the use of combined multi-drug treatments.2015info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf0025-7680http://www.medicinabuenosaires.com/PMID/26707664.pdfhttp://sgc.anlis.gob.ar/handle/123456789/2115Medicina (Buenos Aires) 2015;75(6):396-403.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISMedicina (Buenos Aires)spainfo:eu-repo/semantics/openAccess2025-09-29T14:30:39Zoai:sgc.anlis.gob.ar:Publications/123456789/2115Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-29 14:30:39.927Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false |
dc.title.none.fl_str_mv |
La Tuberculosis a 110 años del premio Nobel de Koch Tuberculosis 110 years after the Nobel Prize awarded to Koch |
title |
La Tuberculosis a 110 años del premio Nobel de Koch |
spellingShingle |
La Tuberculosis a 110 años del premio Nobel de Koch Ritacco, Viviana Tuberculosis Antituberculosos |
title_short |
La Tuberculosis a 110 años del premio Nobel de Koch |
title_full |
La Tuberculosis a 110 años del premio Nobel de Koch |
title_fullStr |
La Tuberculosis a 110 años del premio Nobel de Koch |
title_full_unstemmed |
La Tuberculosis a 110 años del premio Nobel de Koch |
title_sort |
La Tuberculosis a 110 años del premio Nobel de Koch |
dc.creator.none.fl_str_mv |
Ritacco, Viviana de Kantor, Isabel N. |
author |
Ritacco, Viviana |
author_facet |
Ritacco, Viviana de Kantor, Isabel N. |
author_role |
author |
author2 |
de Kantor, Isabel N. |
author2_role |
author |
dc.subject.none.fl_str_mv |
Tuberculosis Antituberculosos |
topic |
Tuberculosis Antituberculosos |
dc.description.none.fl_txt_mv |
Fil: Ritacco, Viviana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Fil: de Kantor, Isabel N. Consultora en Tuberculosis, Buenos Aires; Argentina. The Nobel Prize in Physiology or Medicine was awarded in 1905 to Robert Koch "for his investigations and discoveries in relation to tuberculosis (TB)". He discovered the causal agent of TB, described the four principles that since then have guided research in communicable diseases and also prepared the old tuberculin, a bacillary extract that failed as a healing element but allowed the early diagnosis of TB infection and promoted the understanding of cellular immunity. After his death, the most conspicuous achievements against TB were the BCG vaccine, and the discovery of streptomycin, the antibiotic that launched the era of the effective treatment of TB. Drug-resistance soon appeared. In Argentina, studies on drug resistance began in the 60s. In the 70s, shortened anti-TB drug schemes were introduced consisting in two-month treatment with four drugs, followed by four months with two drugs. The incidence of TB decreased worldwide, but the immune depression associated with awarded together with the misuse of anti-TB drugs allowed the emergence of multidrug resistance and extensive resistance, with the emergence of nosocomial outbreaks worldwide, including Argentina. New rapid diagnostic methods based on molecular biology were developed and also new drugs, but the treatment of multidrug resistant and extensively resistant TB is still difficult and expensive. TB research has marked several milestones in medical sciences, including the monumental Koch postulates, the tuberculin skin test that laid the basis for understanding cell-mediated immunity, the first design of randomized clinical trials and the use of combined multi-drug treatments. |
description |
Fil: Ritacco, Viviana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015 |
dc.type.none.fl_str_mv |
info:ar-repo/semantics/articulo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
0025-7680 http://www.medicinabuenosaires.com/PMID/26707664.pdf http://sgc.anlis.gob.ar/handle/123456789/2115 |
identifier_str_mv |
0025-7680 |
url |
http://www.medicinabuenosaires.com/PMID/26707664.pdf http://sgc.anlis.gob.ar/handle/123456789/2115 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
Medicina (Buenos Aires) |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
Medicina (Buenos Aires) 2015;75(6):396-403. reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" instacron:ANLIS |
reponame_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
collection |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
instname_str |
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
instacron_str |
ANLIS |
institution |
ANLIS |
repository.name.fl_str_mv |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
repository.mail.fl_str_mv |
biblioteca@anlis.gov.ar |
_version_ |
1844621859085090816 |
score |
12.559606 |